Genmab — Maj 2018
-
Jeg sad sjovt nok også lige og genlæste den. Og faldt over denne passage: "There is no information at this time, the Janssen representative told The Beacon, as to how the causes of death differed between the Darzalex-Tecentriq combination therapy arm and the Tecentriq monotherapy arm of the lung cancer trial"
-
Måske i erkendelse af, at faldet mandag var en overreaktion.
-
"However, Pascal Soriot, chief executive of AstraZeneca, which is trialling its own immunotherapy combo, predicts companies will still move quickly because the lucrative field is so hotly contested.
“It’s still a very competitive race and people are ready to take risks,” said Mr Soriot. “Of course, we are going to be looking for monotherapy activity, but if we have a good biological rationale, we may still take the risk with a combination.” -
@Helge, shortere har været diskuteret rigtig meget i dette forum, og det er jo noget, som ryster de private investorer ganske meget, ligesom det også har gjort i mange andre selskaber. Hvad er din holdning - som redaktør af dette betydende medie - til at shorting i andre lande og også tidligere her i landet er forbudt?
-
Jeps...Svarer i Aktiesnakken i aften. Sidder i møder resten af dagen.
-
-
AB er rimeligt neutrale i dag, og kursen har udviklet sig pænt over dagen, så mon ikke vi snart er tilbage på sporet omkring 1100-1200.
-
Tak @bikube, den årsag havde jeg overset.
)Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind